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ABSTRACT: N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trypanosoma
brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously
validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stages 1 and 2 of the disease. We
report on the use of the previously reported DDD85646 (1) as a starting point for the design of a class of potent, brain penetrant
inhibitors of T. brucei NMT.
■ INTRODUCTION
Human African trypanosomiasis (HAT) or sleeping sickness is
prevalent in sub-Saharan Africa1 with an estimated “at risk”
population of 65 million.2 The causative agents of HAT are the
protozoan parasites Trypanosoma brucei gambiense and Trypano-
soma brucei rhodesiense3,4 transmitted through the bite of an
infected tsetse ﬂy. HAT progresses through two stages. In the
ﬁrst stage (stage 1), the parasites proliferate solely within the
bloodstream. In the second, late stage (stage 2), the parasite
infects the central nervous system (CNS) causing the symptoms
characteristic of the disease, such as disturbed sleep patterns and
often death.5 Currently, there are a number of treatments
available for HAT, though none are without issues, including
toxicity and inappropriate routes of administration for a disease
of rural Africa.6
Research has revealed enzymes and pathways that are crucial
for the survival of T. brucei, and based on these studies, a number
of antiparasitic drug targets have been proposed.7−10 T. brucei N-
myristoyltransferase (TbNMT) is one of the few T. brucei
druggable targets to be genetically and chemically validated in
both in vitro and in rodent models of HAT.7,11,12 NMT is a
ubiquitous essential enzyme in all eukaryotic cells. It catalyzes the
co- and post-translational transfer of myristic acid from
myristoyl-CoA to the N-terminal glycine of a variety of peptides.
Protein N-myristoylation facilitates membrane localization and
biological activity of many important proteins.11,13
NMT has been extensively investigated as a potential target for
the treatment of other parasitic diseases including malaria,14
leishmaniasis,15 and Chagas’ disease16,17 resulting in the
identiﬁcation of multiple chemically distinct small molecule
inhibitors.18 NMT has also been shown to be a potential
therapeutic target for human diseases such as autoimmune
disorders19 and cancer.20,21
Previously we have reported the discovery of compound 1
(Figure 1),7,22,23 which showed excellent levels of inhibitory
potency for TbNMT and T. brucei brucei (T. br. brucei)
proliferation in vitro and was used as a model compound to
validate TbNMT as a druggable target for stage 1 HAT.7,22
However, 1 is not blood−brain barrier penetrant, a requirement
for stage 2 activity. Two approaches were taken to increase the
brain penetration of 1. A classical lead optimization approach is
described elsewhere.24 This article describes a second approach
that used a minimum pharmacophore of 1 aiming to derive a
structurally distinct series of potent TbNMT inhibitors with
brain penetration, as leads for the identiﬁcation of suitable
candidates for the treatment of stage 2 HAT.
■ COMPOUND RATIONALE AND DESIGN
To aid compound design, and to signiﬁcantly lower molecular
weight and polar surface area (PSA), the chlorines and the
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sulfonamide moieties of 1 were removed to deﬁne a minimum
pharmacophoric scaﬀold (Figure 2A). This scaﬀold was chosen
because the piperidine makes a key interaction through the
formation of a salt bridge with NMT’s terminal carboxylate.10
This interaction is highly conserved across the binding modes of
NMT inhibitors covering multiple chemotypes including 1
(Figure 2B); known antifungal NMT inhibitors such as Roche’s
(2 -benzofurancarboxy l i c ac id , 3 -methy l -4 -[3 -[(3-
pyridinylmethyl)amino]propoxy]-ethyl ester (RO-09-
4609),26,27 Searle’s N-[2-[4-[4-(2-methyl-1H-imidazol-1-yl)-
butyl]phenyl]acetyl]-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
(SC-58272)28 (Figure 2C), and Pﬁzer’s 2-((1R,4R)-4-
(aminomethyl)cyclohexanecarboxamido)-N,N-dimethylbenzo-
[d]thiazole-6-carboxamide (UK-370,485).29 Attempts to crys-
tallize TbNMT had proved to be unsuccessful; therefore, the
fungal Aspergillus fumigatus NMT (AfNMT)24,30 was used as a
surrogate model for TbNMT in this study. AfNMT is 42%
identical to TbNMT; however, within the peptide binding
groove the level of identity is 92%. Previously, a selection of
molecules from series 1 were assayed against AfNMT and
TbNMT using the SPA biochemical assay and pIC50 values
compared using linear regression analysis. The pIC50 values were
shown to be correlated with an R-squared value of 0.73
suggesting that AfNMT is a suitable surrogate system for study
within this chemical series (see Supporting Information).
This minimum pharmacophoric scaﬀold had low molecular
weight (237) and low PSA (12 Å2 to maximize the potential for
CNS penetration) from which we could design varied chemistry
(Figure 2A) to either access the serine pocket (occupied by the
pyrazole moiety in 1) or the peptide recognition region, as seen
in the peptomimetic compound highlighted in red (Figure 2C).
Compound Design. The adopted compound design
strategy covered both compounds based on 1 (where common
sulfonamide bioisosteres31 and pyrazole mimics were included)
and compounds based on the binding pocket structural features,
probing these with diverse hydrogen bond acceptor (HBA) and
hydrogen bond donor (HBD) groups. We employed high
throughput chemistry, using technologies and techniques such as
scavengers and solid supported reagents enabling arrays to be
made in parallel. Three diﬀerent but complementary chemistries
Figure 1. Compound 1. *Potencies were determined against
recombinant TbNMT and HsNMT1, and against bloodstream form
T. brucei brucei (T. br. brucei) and MRC-5 proliferation studies in vitro
using 10 point curves replicated ≥2. aCalculated using Optibrium
STARDROP software. bLigand eﬃciency (LE), calculated as 0.6·
ln(IC50)/(heavy atom count) using T. bruceiNMT IC50 potency.
25 IC50
values are shown as mean values of two or more determinations.
Standard deviation was typically within 2-fold from the IC50.
cEnzyme
selectivity calculated as HsNMT1 IC50 (μM)/TbNMT IC50 (μM).
Figure 2. Development of the chemistry scaﬀold. (A) Two-dimensional interaction map of 1 bound to AfNMT leading to the design of the minimal
scaﬀold. (B) Crystal structure of 1 bound; key recognition residues are highlighted and labeled. (C) Proposed minimal scaﬀold (C atoms gold) docked
into the crystal structure of AfNMT overlaid with peptomimetic compound PDB 2NMT (C atoms cyan); the key S/T K peptide recognition region is
highlighted red.
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of Suzuki couplings, amidations, and Mitsunobu reactions were
chosen to explore all positions around ring A (Figure 3).
Crossing the blood−brain barrier (BBB) was an essential part
of our chemistry design and presented its own challenges.
Improving the BBB permeation of molecules has been widely
studied and in silico prediction methods developed based on
known CNS penetrant and nonpenetrant compounds.32,33
Examination of the physicochemical properties of molecules
and their inﬂuence on aﬀecting BBB permeability has suggested
some guiding principles and a physicochemical property range to
increase the probability of improving the BBB permeability.33
The top 25% CNS penetrant drugs sold in 2004 were found to
have mean values of PSA (Å2) 47, HBD 0.8, cLogP 2.8, cLogD
(pH 7.4) 2.1, and MW 293. They suggested the following
maximum limits when designing compounds as PSA < 90 Å2,
HBD < 3, cLogP 2−5, cLogD (pH 7.4) 2−5, MW < 500. As this
was the ﬁrst round of compound design, we restricted the
compounds to the following parameters: PSA 40−70 Å2, HBD <
3, cLogP 2−4.5, MW 250−400.
Virtual libraries of all possible compounds that could be
constructed from our in-house chemical inventory were
constructed and minimized to ensure that a wide region of
chemical space was explored, and structures were not biased to
one region. Reaction schemes, intermediates, and examples of
compounds made are described in the Supporting Information.
■ RESULTS AND DISCUSSION
Scaﬀold Array Results. No compounds made in the Suzuki
chemistry (1, Figure 3) derived series had a potency <10 μM
against TbNMT (see Supporting Information for compounds
made). Table 1 shows the potency against TbNMT for selected
examples from the amide (3−7), homologated amide (8−12),
and ether series (17−24). The most potent compound in the
amide series was 3 (TbNMT IC50 1.7 μM). Amides directly
linked to the phenyl ring in the 3-position were found to be more
potent than the corresponding 4-substituted analogues (5 vs 4
and 7 vs 6). The homologated amide series in comparison to the
amide series were on the whole >3-fold more potent (6 vs 12)
with the most potent compound achieving a TbNMT IC50 value
of 0.07 μM (10). In the homologated amides series the 4-
position amides showed greater potency than the corresponding
3-position analogues (the opposite trend to the amide series).
Further optimization of both the directly linked and homo-
logated amide series failed to improve the potency or the
pharmacokinetic properties.
The ether array produced compounds with good levels of
activity against TbNMT, the most active of these achieved an
IC50 value of 0.5 μM (24). The more potent compounds were
substituted in the 4-position, on average showing around 10-fold
greater potency over their 3-position analogues, e.g., 3-position
compound 22 (35 μM) vs 4-position compound 23 (1.2 μM) or
3-position compound 20 (13 μM) vs 4-position compound 21
(1.4 μM). Interestingly, the replacement of the sulfonamide in
structure 1 with an ether linkage (17) was completely inactive
against TbNMT (IC50 > 100 μM). This was surprising, as methyl
ethers are considered possible sulfonamide bioisosteres.31
Compound 24 was not selective over human NMT
(HsNMT1) but exhibited an EC50 of 2 μM in the T. br. brucei
proliferation assay, with good microsomal stability and moderate
levels of selectivity against proliferating human MRC-5 cells
(Figure 4).
The crystal structure of 24 bound to AfNMT (Figure 4A)
shows the ligand binds in the peptide binding groove in an overall
U-shaped conformation, with the ligand wrapping round the side
chain of Phe157. The central aryl rings of 24 lie perpendicular to
each other allowing the ligand to sit in the cleft formed by the side
Figure 3. Scaﬀold array chemistry and design. aFilter parameters calculated using the Optibrium STARDROP software.
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chain of Tyr263, Tyr393, and Leu436. The cleft is formed by the
movement of the side chain of Tyr273; a feature observed in the
binding mode of benzofuran ligands26,27 and subsequent
derivatives.34
The pyridyl nitrogen of 24 forms an interaction with Ser378 in
a similar orientation as the trimethyl-pyrazole group of 1, and the
piperidine moiety interacts directly with the C-terminal carboxyl
group of Leu492.
Compound 24 does not interact with His265, an interaction
formed by the sulfonamide in 1 (overlaid with 24, Figure 4B),
which potentially explained the drop oﬀ in potency between 1
(TbNMT 0.002 μM) and 24 (0.5 μM). Despite this loss of
activity, 24 had comparable ligand eﬃciency (LE)35 of 0.33 to 1,
LE = 0.36, and in combination with the observed binding mode,
gave us conﬁdence that the design strategy was valid.
Optimization of Compound 24.With the aim of increasing
potency against TbNMT, the diphenyl piperidine ring was
replaced with the dichlorophenyl-pyridyl-piperidine moiety of 1.
This change reduced the logP by∼1 log unit from 4.3 for 24, with
an increase in PSA from 34 Å2 (19) to 50 Å2, which was within
the acceptable guidance limits for BBB permeability32,33 to give
29 (synthesis shown in Scheme 1).
Compound 29 (Figure 5) exhibited a 4-fold improvement in
potency against TbNMT (IC50 0.1 μM) and improved eﬃcacy in
theT. br. brucei proliferation assay (EC50 0.7 μM), while retaining
good microsomal stability (1.4 mL/min/g) and LE (0.33).
Encouragingly, 29 showed good levels of brain penetration
(brain−blood = 0.4), a signiﬁcant improvement over 1 (brain−
blood < 0.1),22 indicating that the strategy of reducing MW and
PSA was a valid approach (1, PSA 101 Å, MW 495). The crystal
structure of 29 bound to AfNMT (Figure 6) was determined
Table 1. Array Chemistry Selected Results for the Amide, Homologated Amides, and Ether Series
*Compounds greater than 90% pure. aCompounds >95% pure. bIC50 values are shown as mean values of two or more determinations. Standard
deviation was typically within 2-fold from the IC50. nd = not determined.
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showing the ligand adopted a conformation similar to 1 with the
biaryl system sitting in plane with the 2,6-dichlorophenyl ring
stacking in plane with the side chain of Tyr273. Key interactions
between the piperidine N to Ser378 and the piperazine to the C-
terminal carboxyl group are retained from 24.
Replacement of the 2,6-Dichlorophenyl Ring. Opti-
mization of 29 focused on modiﬁcations to the central 2,6-
dichlorophenyl ring to increase enzymatic selectivity relative to
HsNMT1 (0.3 μM, 3-fold compared to TbNMT IC50). These
modiﬁcations were made employing the same chemistry as
outlined in Scheme 1, by varying the starting substituted
bromophenol used in the Mitsunobu step. These 2,6-
dichlorophenyl modiﬁcations are detailed in Table 2.
None of the core modiﬁcations improved potency against
TbNMT when compared to 29 (Table 2) nor LE and enzyme
selectivity, although some demonstrated increased levels of
potency against HsNMT1 (37, HsNMT1, IC50 0.01 μM). The
reason for this increase in HsNMT1 activity was not explained
using the available crystal structure data. Certainly inhibitors of
human NMT such as 37 are of potential interest in the treatment
of cancer,20 and further elaboration of the core could be explored.
Pyridyl Headgroup SAR. The next phase of optimization
focused on modiﬁcations to the ether pyridyl ring of 29 shown in
Table 3. These compounds were made using the same common
phenol intermediate (Scheme 2), applying solid phase reagents
such as polystyrene bound triphenylphosphine, and running
reactions and puriﬁcations in parallel using commercially
available alcohols or alcohols derived from commercially
available carboxylic acids or esters after reduction with borane
or lithium aluminum hydride (see Supporting Information).
Modiﬁcations to the pyridyl headgroup showed encouraging
results with 47 equipotent to 29 (IC50 ≈ 0.1 μM) but with ∼65-
fold selectivity over HsNMT1, equivalent activity in the T. br.
brucei proliferation assay, and promising microsomal stability
(Cint 4.2 mL/min/g). Compound 30, though, had equivalent
activity to 29 in the MRC-5 counter screen, indicating that
HsNMT1 activity may not have been driving theMRC-5 toxicity.
Homologation of the linker to the pyridyl group did not
improve potency, as did groups on the pyridyl ring at the 6- (48)
or 4-positions (49), though both 48 and 49 showed equivalent
activity in the T. br. brucei proliferation assay to 29. The crystal
structure of 29 overlaid with the trimethylpyrazole of 1 suggested
that additions of methyl substitution may have been beneﬁcial to
potency (Figure 7A) because the trimethyl substitution of
pyrrole in 1 was essential for activity. Subsequent crystal
structures of 48 showed that the binding pocket the pyridyl
headgroup accesses is small and that these substituents in the
case of 49 forced the ether pyridyl ring to twist in the pocket to
avoid steric clashes with its dichlorophenyl ring, and for 48, the 4-
methyl forces the pyridyl ring out of the pocket. In both cases, the
direct hydrogen bond from the pyridyl nitrogen to the serine was
broken, but 48 still formed an interaction, though this was now
water mediated (Figure 7B).
Alternative Nonpyridyl Head Group SARs. To advance
the series, two regions within the structure were modiﬁed with
the aim to improve potency, ﬁrst examining pyridyl replacements
and modiﬁcations to the pyridyl ring and replacement of the
piperazino-pyridine moiety. First, the pyridyl ring was replaced
with a range of ﬁve-membered heterocycles, mainly thiazoles,
with various substitutions; see Table 4. The most potent of these
showed levels of promising activity against TbNMT (IC50 ≈
0.05−0.06 μM; 58 and 57). The SAR around 57 was tight. The
removal of either methyl groups (60 and 65) lost activity against
TbNMT; in addition, substitution of the 2-methyl group with
either ethyl (64) or isopropyl (66) lost all activity in the T. br.
brucei proliferation assay. Compound 57 showed good stability
to microsomal turnover (Cint 2.4 mL/min/g) but also improved
selectivity over MRC-5 cytotoxicity. Both 58 and 57 showed
equivalent levels of potency againstHsNMT1 (IC50≈ 0.03−0.08
μM) and again showed very diﬀerent MRC-5 activities,
indicating that MRC-5 toxicity may not be entirely driven by
HsNMT1 activity.
Replacement of the Piperazino-Pyridine Moiety. We
had previously validated TbNMT as a druggable target in the
Figure 4. Binding mode of 24. (A) Compound 24 (C atoms gold)
bound to AfNMT (C atoms gray). PDB 5T5U. H-bonds are shown as
dashed lines and key residues labeled. (B) Comparison of the binding
mode of 24 with 1 bound to AfNMT (PDB 4CAX), highlighting the
movement of Tyr273. Compound 1 and the side chain of Tyr273 (PDB
4CAX) are shown with cyan C atoms.
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stage 2 model for HAT in mice using 68 as a model compound
(Figure 8A).24 Compound 68 showed good potency in the T. br.
brucei proliferation assay at EC50 0.001 μM and improved levels
of selectivity over MRC-5 cells when compared to 1. We
examined hybridizing the 4-C chain derivative of 68, 69, which
showed equally good eﬃcacy and potency, and 29 to increase
eﬃcacy in the T. br. brucei proliferation assay. Compound 71
(synthesis in Scheme 3) showed increased selectivity over MRC-
5 cells andHsNMT1 but showed a signiﬁcant drop oﬀ in eﬃcacy
in the T. br. brucei proliferation assay. This was potentially caused
by the signiﬁcant increase in lipophilicity of 71 (logP 5.5)
compared to 29 (logP 3.4), resulting in an increased level of
nonspeciﬁc protein/membrane binding. Given the more
favorable logP of 29, further optimization focused on derivatives
of 29 rather than 71. Compound 70 (Scheme 3), the NH
piperidine of 71, showed no in vitro activity against TbNMT.
Pyridyl Headgroup Optimization. The crystal structure of
29 (Figure 6) indicated that themethyl substituent on the pyridyl
ring was pointing into a small pocket. Chemistry was developed
to explore this pocket with various hydrophobic and polar groups
as detailed in Scheme 4. Using a common intermediate (ethyl 2-
chloronicotinate, 72), Suzuki and Negishi reactions were used to
install aromatics rings (73) and alkyl groups (74a−c),
respectively. Amines were installed through displacement of
the chlorine of 72. After reduction of the ethyl esters (73−75) to
the corresponding alcohols (76−78), they were reacted using
standard Mitsunobu conditions (Scheme 2) to give ﬁnal
products detailed in Table 5.
Good levels of inhibition of TbNMT were observed for all
compounds prepared (except 79), some with improved potency
over 29. The loss of activity of 79 was most probably caused by
the alkoxy-group reducing the basicity of the pyridine ring,
making the ring nitrogen a poorer HBA. Compounds 81 and 82
showed promising potency against the parasite (EC50 = 0.1 μM),
with good selectivity compared to MRC-5 cells (81), and had
good microsomal stability (81, 1.2 mL/min/mg; 82, 1.6 mL/
min/mg). Compound 81 (Figure 9) showed signiﬁcant levels of
brain penetration (brain−blood ratio = 1.9), a signiﬁcant
improvement on 29 (brain−blood ratio 0.4) and 1 (brain−
blood ratio < 0.1). Compound 81 represents a good lead for
further optimization to identify development candidates for stage
2 HAT.
■ CONCLUSIONS
By using 1 as a starting point to identify alternative TbNMT
inhibitor scaﬀolds with physicochemical properties suitable for
penetration into the brain to treat stage 2 HAT, we identiﬁed an
ether linker as a replacement of the sulfonamide of 1. This
modiﬁcation reduced molecular weight and polar surface area,
producing a viable alternative series with excellent levels of brain
penetration. This work highlights the importance of decreasing
the PSA as a way of increasing the probability of brain
penetration. Further optimization identiﬁed compounds with
good levels of TbNMT and T. br. brucei antiproliferative activity
and microsomal stability. Though in comparison with the
original structure 1, further potency gains against the enzyme and
in the parasite proliferation assay are required. This series
Scheme 1a
aReagents and conditions: (a) polymer supported-PPh3, DIAD, alcohol, THF; (b) dioxane/1 M aq K3PO4, Pd(PPh3)4; (c) TFA, DCM; (d) 2 M
HCl in diethyl ether.
Figure 5. Compound 29 proﬁle. aValues calculated using the Optibrium
STARDROP software. bLigand eﬃciency (LE), calculated as 0.6·
ln(IC50)/(heavy atom count) using T. bruceiNMT IC50 potency.
25 IC50
values are shown as mean values of two or more determinations.
Standard deviation was typically within 2-fold from the IC50. nd = not
determined. cEnzyme selectivity calculated as HsNMT1 IC50 (μM)/
TbNMT IC50 (μM).
Figure 6. Binding mode of 29 (C atoms gold) bound to AfNMT (PDB
5T6C). Binding mode of 1 (C atoms cyan) is shown for comparison.
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presents good leads to identify potential development candidates
for stage 2 HAT.
■ EXPERIMENTAL SECTION
Synthetic Materials and Methods. Chemicals and solvents were
purchased from the Aldrich Chemical Co., Fluka, ABCR, VWR, Acros,
Fisher Chemicals, and Alfa Aesar and were used as received unless
otherwise stated. Air- and moisture-sensitive reactions were carried out
under an inert atmosphere of argon in oven-dried glassware. Analytical
thin-layer chromatography (TLC) was performed on precoated TLC
plates (layer 0.20 mm silica gel 60 with ﬂuorescent indicator UV254,
fromMerck). Developed plates were air-dried and analyzed under a UV
lamp (UV254/365 nm). Flash column chromatography was performed
using prepacked silica gel cartridges (230−400 mesh, 40−63 μm, from
SiliCycle) using a Teledyne Presearch ISCO Combiﬂash Companion
4X or Combiﬂash Retrieve. 1H NMR and 13C NMR spectra were
recorded on a Bruker Avance II 500 spectrometer (1H at 500.1 MHz,
13C at 125.8 MHz) or a Bruker DPX300 spectrometer (1H at 300.1
MHz). Chemical shifts (δ) are expressed in ppm recorded using the
residual solvent as the internal reference in all cases. Signal splitting
patterns are described as singlet (s), doublet (d), triplet (t), quartet (q),
pentet (p), multiplet (m), broad (br), or a combination thereof.
Coupling constants (J) are quoted to the nearest 0.1 Hz. LC−MS
analyses were performed with either an Agilent HPLC 1100 series
connected to a Bruker Daltonics micrOTOF or an Agilent Technologies
1200 series HPLC connected to an Agilent Technologies 6130
quadrupole LC−MS, where both instruments were connected to an
Agilent diode array detector. LC−MS chromatographic separations
were conducted with a Waters Xbridge C18 column, 50 mm × 2.1 mm,
3.5 μm particle size; mobile phase, water/acetonitrile + 0.1% HCOOH,
or water/acetonitrile + 0.1% NH3; linear gradient 80:20 to 5:95 over 3.5
min, and then held for 1.5 min; ﬂow rate 0.5 mL min−1. All assay
compounds had a measured purity of ≥95% (by TIC and UV) as
determined using this analytical LC−MS system; a lower purity level is
indicated. High-resolution electrospray measurements were performed
on a Bruker Daltonics MicrOTOF mass spectrometer. Microwave-
assisted chemistry was performed using a Biotage Initiator Microwave
Synthesizer.
tert-Butyl-4-(3-Bromophenyl)piperidine-1-carboxylate (14). A sol-
ution of 4-(3-bromophenyl)piperidine·hydrochloride (13) (5.1 g, 18.4
mmol, 1 equiv), Boc2O (4.4 g, 20.2 mmol, 1.1 equiv), and triethylamine
(3.87 mL, 27.8 mmol, 1.5 equiv) in THF (50 mL) was stirred at room
temperature for 16 h. The reaction was ﬁltered, and the ﬁltrate was
washed with dilute 10% citric acid and extracted into ethyl acetate. The
ethyl acetate layer was washed with water, then dried over MgSO4,
ﬁltered, and evaporated to give an oﬀ-white solid (14) (6.13 g, 98%
yield). 1H NMR, 500 MHz, CDCl3 δ1.51 (s, 9H), 1.57−1.66 (m, 2H),
1.81−1.86 (m, 2H), 2.64 (tt, J = 3.70, 12.21, 1H), 2.77−2.85 (m, 2H),
4.22−4.32 (m, 2H), 7.14−7.22 (m, 2H), 7.35−7.39 (m, 2H). [M + H]+
= 388.4.
tert-Butyl 4-(3′-Hydroxy-[1,1′-biphenyl]-3-yl)piperidine-1-carbox-
ylate (15). tert-Butyl 4-(3-bromophenyl)piperidine-1-carboxylate (14)
(2 g, 5.88 mmol, 1 equiv), 3-hydroxyphenyl boronic acid (974 mg 7.06
mmol, 1.2 equiv), anhydrous dioxane (10 mL), and 1 M aq K3PO4 (6
mL) were combined in a microwave vessel and argon bubbled through
the mixture for 5min. Pd(PPh3)4 (136mg, 0.118mmol, 2%), was added,
and the reaction was degassed again for a further 5 min before
microwaving at 140 °C for 15 min. The resulting solution was extracted
into dichloromethane, washed with sat. aq NaHCO3, and passed
Table 2. Modiﬁcations to the 2,6-Dichorophenyl Central Ring of Compound 29
aIC50 values are shown as mean values of two or more determinations. Standard deviation was typically within 2-fold from the IC50. nd = not
determined. bLigand eﬃciency (LE), calculated as 0.6·ln(IC50)/(heavy atom count) using T. brucei NMT IC50 potency.
25 cEnzyme selectivity
calculated as HsNMT1 IC50 (μM)/TbNMT IC50 (μM).
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through a phase separation cartridge. The organic layer was then
absorbed onto silica and puriﬁed by ﬂash column chromatography
running a gradient from 0% ethyl acetate/hexane to 50% ethyl acetate/
hexane to give 15 as a colorless oil (1.76 g, 85% yield). 1H NMR 500
MHz, CDCl3 δ 1.53 (s, 9H), 1.60−1.76 (m, 2H), 1.83−1.91 (m, 2H),
2.71 (tt, J = 3.68, 12.33, 1H), 2.70−2.91 (m, 2H), 4.24−4.35 (m, 2H),
6.36 (s, 1H), 6.88 (dd, J = 2.50, 8.11, 1H), 7.10−7.20 (m, 3H), 7.28−
7.46 (m, 4H).
tert-Butyl 4-(4′-Hydroxy-[1,1′-biphenyl]-3-yl)piperidine-1-carbox-
ylate (16). A mixture of 4-hydroxyphenylboronic acid (183 mg, 1.32
mmol, 1 equiv), tert-butyl 4-(3-bromophenyl)piperidine-1-carboxylate
(14) (450 mg, 1.32 mmol, 1 equiv), Pd(PPh3)4 (30 mg), and K3PO4 (1
equiv) in DMF−H2O (3:1, 4 mL) aﬀorded 16 (326 mg, 70% yield). 1H
NMR 500 MHz, DMSO, δ 1.56 (s, 9H), 1.68−1.74 (m, 2H), 1.86−1.96
(m, 2H), 2.72−2.80 (m, 1H), 2.80−3.00 (m, 2H), 4.29−4.32 (br. s, 2H),
5.02 (s, 1H), 6.96−6.99 (m, 2H), 7.18−7.21 (m, 1H), 7.39−7.48 (m,
3H), 7.52−7.56 (m, 2H). [M + H]+ = 354.2331, 298.1651 (product −
tBu).
4-(3′-((1,3,5-Trimethyl-1H-pyrazol-4-yl)methoxy)-[1,1′-biphenyl]-
3-yl)piperidine (17). tert-Butyl 4-(3′-hydroxy-[1,1′-biphenyl]-3-yl)-
piperidine-1-carboxylate (15) (100 mg, 0.28 mmol, 1 equiv), (1,3,5-
trimethylpyrazole)methanol (44 mg, 0.31 mmol, 1.1 equiv), polystyrene
bound-PPh3 (PPh3 = triphenylphosphine, 1.84 mmol/g loading, 228
Table 3. Pyridyl Head Group SAR of Compound 29
aIC50 values are shown as mean values of two or more determinations. Standard deviation was typically within 2-fold from the IC50. nd = not
determined. bLigand eﬃciency (LE), calculated as 0.6·ln(IC50)/(heavy atom count) using T. brucei NMT IC50 potency.
25 cEnzyme selectivity
calculated as HsNMT1 IC50 (μM)/TbNMT IC50 (μM).
Scheme 2a
aReagents and conditions: (a) Boc2O, NEt3, THF; (b) 4-bromo-2,6-dichlorophenol, MeCN/1 M aq K3PO4, Pd(dppf)2Cl2; (c) PS−PPh3, DIAD,
alcohol, THF; (d) TFA, DCM.
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mg, 0.42 mmol, 1.5 equiv), diisopropyl azodicarboxylate (DIAD, 66 μL,
0.34 mmol, 1.2 equiv) in anhydrous dioxane (5 mL) in a capped test
tube was heated at 60 °C for 16 h. The reaction was absorbed onto silica
and puriﬁed by ﬂash column chromatography running a gradient from
0% ethyl acetate/hexane to 100% ethyl acetate. The resulting product
was evaporated in vacuo before dissolving in dichloromethane (10 mL),
addition of triﬂuoroacetic acid (10 equiv) and stirring at RT for 3 h. The
reaction was then evaporated in vacuo before dissolving in dichloro-
methane and loading onto a prewashed SCX cartridge. The SCX
cartridge was washed with dichloromethane (3× 10 mL) andMeOH (3
× 10 mL) before eluting the product with 7 N ammonia in methanol.
This was evaporated to give 17 (64 mg, 61% yield). 1H NMR 500 MHz,
CDCl3 δ 1.66 (s, 3H), 1.67−1.75 (m, 2H), 1.87−1.92 (m, 2H), 2.70−
2.77 (m, 1H), 2.80−2.89 (m, 2H), 3.76 (s, 3H), 4.22−4.35 (m, 2H),
4.90 (s, 2H), 6.39 (br. s, 1H), 6.98−7.01 (m, 1H), 7.20−7.23 (m, 3H),
7.37−7.47 (m, 4H). [M + H] = 427.2.
Compounds 14−20 were made in an analogous manner to 17 from
16, see Supporting Information for analytical data.
Prototypical Mitsunobu Reaction of a Pyridyl Alcohol and a
Substituted Phenol (Scheme 1). See Supporting Information for the
synthesis of intermediates 30−35 for compounds 36−41 (Table 2).
3-((4-Bromo-2,6-dichlorophenoxy)methyl)-2-methylpyridine (27).
DIAD (diisopropyl azodicarboxylate, 5 mL, 24.8 mmol, 1.2 equiv) was
added to a suspension of 4-bromo-2,6-dichlorophenol (25) (5.0 g, 20.7
mmol, 1 equiv), 2-methyl-3-hydroxymethylpyridine (26) (3.1 g, 24.8
mmol, 1.2 equiv), and polystyrene bound-PPh3 (1.84 mmol/g loading,
16.2 g, 29.8 mmol, 1.2 equiv) in anhydrous THF (20 mL) then heated at
70 °C for 4 h. After cooling, the reaction mixture was ﬁltered, the beads
washed with MeOH and dichloromethane, and the ﬁltrate concentrated
in vacuo. The resulting residue was triturated with MeOH to give 27 as a
white solid (5.46 g, 76% yield). 1H NMR 500 MHz, CDCl3 δ 2.68 (s,
3H), 5.03 (s, 2H), 7.18 (dd, J = 4.90, 7.68 Hz, 1H), 7.49 (s, 3H), 7.82
(dd, J = 1.68, 7.68 Hz, 1H), 8.50 (dd, J = 1.68, 4.90 Hz, 1H). LC−MS [M
+ H]+ = 347.9.
tert-Butyl 4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-
pyridin-2-yl)piperazine-1-carboxylate (28). A solution of 1-(4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine
(2.97 g, 10.27 mmol, 1 equiv), di-tert-butyl-dicarbonate (Boc2O, 2.5 g,
11.3 mmol, 1.1 equiv), in THF (20 mL) and triethylamine (2.1 mL, 15.4
mmol, 1.5 equiv) was stirred at RT overnight. The resulting reaction was
extracted into dichloromethane, and then washed with 10% citric acid
and then water. The dichloromethane layer was dried over MgSO4,
ﬁltered and evaporated to give (28) as a white solid (4 g, 100% yield). 1H
NMR 500 MHz, CDCl3 δ 1.28 (s, 12H), 1.42 (s, 9H), 3.45−3.50 (m,
8H), 6.90 (d, J = 4.91, 1H), 6.97 (s, 1H), 8.14 (dd, J = 1.02, 4.89, 1H).
[M + H]+ = 389.45.
Prototypical Suzuki Reaction of an Aryl Bromide and a Boronate
Ester (Compounds 29−35). 1-(4-(3,5-Dichloro-4-((2-methylpyridin-
3-yl)methoxy)phenyl)pyridin-2-yl)piperazine Dihydrochloride Salt
(29). tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
pyridin-2-yl)piperazine-1-carboxylate (28) (67 mg, 0.23 mmol, 1
equiv), 3-((4-bromo-2,6-dichlorophenoxy)methyl)-2-methylpyridine
(27) (80 mg, 0.23 mmol, 1 equiv), and potassium phosphate·trihydrate
(49 mg, 0.231 mmol, 1 equiv) in DMF−H2O (1:1, 4 mL) was combined
in a microwave vessel and degassed with argon for 5 min, before the
addition of Pd(PPh3)4 (14 mg, 0.012 mmol, 5%), and reaction degassed
again, then microwaved at 100 °C for 40 min. Reaction was
concentrated in vacuo, extracted into dichloromethane, and then washed
with aq NaHCO3. The two-phase system was passed through a phase
separation cartridge, the ﬁltrate concentrated in vacuo, and the title
compound puriﬁed by ﬂash column chromatography using 8% MeOH/
ethyl acetate + 1% aq NH3 as the eluent. The residue was taken up in
dichloromethane, ethereal HCl was added (2 M, 2 mL) and
concentrated, and the dihydrochloride salt of 29 was triturated with
ether, ﬁltered, and washed with ether (104mg, 71% yield). 1HNMR 500
MHz, d6-DMSO δ 2.82 (s, 3H), 3.17−3.23 (m, 4H), 3.85−3.90 (m,
4H), 5.29 (s, 2H), 7.16 (d, J = 5.20 Hz, 1H), 7.27−7.30 (m, 1H), 7.78−
7.86 (m, 1H), 8.06 (s, 2H), 8.22 (d, J = 5.20 Hz, 1H), 8.41−8.51 (m,
1H), 8.71−8.77 (m, 1H), 9.15 (br s, 2H). HRMS [M + H]+ calculated
for C22H23Cl2N4O1 = 429.1243, found = 429.1240.
1-(4-(4-((2-Methylpyridin-3-yl)methoxy)phenyl)pyridin-2-yl)-
piperazine Dihydrochloride Salt (36). Prepared from 3-((4-
bromophenoxy)methyl)-2-methylpyridine (30) (150 mg, 0.54 mmol,
1 equiv) and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-
2-yl)piperazine 28 (156 mg, 0.54 mmol, 1 equiv), according to the
method outlined for the synthesis of 29, to give 36 as a dihydrochloride
salt (150 mg, 64% yield). 1H NMR 500 MHz, DMSO δ 2.79 (s, 2H),
3.21−3.27 (m, 4H), 3.93−3.98 (m, 4H), 5.40 (s, 2H), 7.21−7.30 (m,
3H), 7.35−7.43 (m, 1H), 7.86−7.95 (m, 3H), 8.15 (d, J = 6.00 Hz, 1H),
8.53 (d, J = 7.45Hz, 1H), 8.74 (d, J = 5.75 Hz, 1H), 9.39 (br s, 2H). LC−
MS [M + H]+ = 361.2. HRMS [M + H]+ calculated for C22H25N4O1 =
361.2023, found = 361.2033.
1-(4-(2,5-Diﬂuoro-4-((2-methylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine Dihydrochloride (37). Prepared from 3-((4-
bromo-2,5-diﬂuorophenoxy)methyl)-2-methylpyridine (31) (106 mg,
0.34 mmol, 1 equiv) and 28 (98 mg, 0.34 mmol, 1 equiv), according to
the method outlined for the synthesis of 29, to give 37 as a
dihydrochloride salt (124 mg, 78% yield). 1H NMR 500 MHz,
DMSO δ 2.79 (s, 3H), 3.17−3.23 (m, 4H), 3.84−3.90 (m, 4H), 5.48
(s, 2H), 6.99−7.03 (m, 1H), 7.14−7.19 (m, 1H), 7.57 (dd, J = 7.20,
12.20 Hz, 1H), 7.75 (dd, J = 7.33, 11.83 Hz, 1H), 7.90 (t, J = 7.90 Hz,
1H), 8.20 (d, J = 5.55Hz, 1H), 8.49 (d, J = 7.25Hz, 1H), 8.76 (d, J = 5.65
Hz, 1H), 9.32 (br s, 2H). LC−MS [M + H]+ = 397.2. HRMS [M + H]+
calculated for C22H23F2N4O1 = 397.1834, found = 397.1848.
1-(4-(2-Fluoro-4-((2-methylpyridin-3-yl)methoxy)phenyl)pyridin-
2-yl)piperazine Dihydrochloride (38). Prepared from 3-((4-bromo-3-
ﬂuorophenoxy)methyl)-2-methylpyridine (32) (100 mg, 0.34 mmol, 1
equiv) and 28 (98 mg, 0.34 mmol, 1 equiv), according to the method
outlined for the synthesis of 29, to give 38 as a dihydrochloride salt (110
mg, 72% yield). 1H NMR 500 MHz, DMSO δ 2.81 (s, 3H), 3.19−3.25
(m, 4H), 3.89−3.96 (m, 4H), 5.42 (s, 2H), 7.02−7.08 (m, 1H), 7.13
(dd, J = 1.85, 8.35 Hz, 1H), 7.25 (dd, J = 1.63, 12.88 Hz, 1H), 7.70 (t, J =
8.65 Hz, 1H), 7.92 (t, J = 6.48 Hz, 1H), 8.17 (d, J = 5.65 Hz, 1H), 8.55
(d, J = 7.65 Hz, 1H), 8.75 (d, J = 5.05 Hz, 1H), 9.47 (br s, 2H). LC−MS
Figure 7. Binding mode of pyridyl headgroup modiﬁcations. (A) Binding mode of 49 (C atoms aquamarine; PDB 5T6H) compared with 29 (C atoms
gold). The side chain of Phe278 rotates to accommodate the 4-methyl group. (B) Binding mode of 48 (C atoms aquamarine; PDB 5T6E); the
interaction with Ser378 is now a water bridged interaction. (C) Compound 48 compared with 29.
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[M + H]+ = 379.2. HRMS [M + H]+ calculated for C22H24F1N4O1 =
379.1929, found = 379.1942.
1-(4-(2,6-Diﬂuoro-4-((2-methylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine Dihydrochloride (39). Prepared from 3-((4-
bromo-3,5-diﬂuorophenoxy)methyl)-2-methylpyridine (33) (106 mg,
0.34 mmol, 1 equiv) and 28 (98 mg, 0.34 mmol, 1 equiv), according to
the method outlined for the synthesis of 29, to give 39 as a
dihydrochloride salt (109 mg, 69% yield). 1H NMR 500 MHz,
DMSO δ 2.77 (s, 3H), 3.16−3.21 (m, 4H), 3.77−3.82 (m, 4H), 5.40
(s, 2H), 6.82 (d, J = 4.95 Hz, 1H), 7.03−7.07 (m, 1H), 7.14 (d, J = 9.90
Hz, 2H), 7.86−7.91 (m, 1H), 8.23 (d, J = 5.20 Hz, 1H), 8.49 (d, J = 6.30
Hz, 1H), 8.75 (d, J = 5.45 Hz, 1H), 9.20 (br s, 2H). LC−MS [M +H]+ =
397.2. HRMS [M + H]+ calculated for C22H23F2N4O1 = 397.1834,
found = 397.1852.
1-(4-(2-Methyl-4-((2-methylpyridin-3-yl)methoxy)phenyl)pyridin-
2-yl)piperazine Dihydrochloride (40). Prepared from 3-((4-bromo-3-
methylphenoxy)methyl)-2-methylpyridine (34) (150 mg, 0.51 mmol, 1
equiv) and 28 (148 mg, 0.51 mmol, 1 equiv), according to the method
outlined for the synthesis of 29, to give 40 as a dihydrochloride salt (110
mg, 48% yield). 1HNMR 500MHz, DMSO δ 2.29 (s, 3H), 2.77 (s, 3H),
3.17−3.23 (m, 4H), 3.83−3.88 (m, 4H), 5.34 (s, 2H), 6.80−6.84 (m,
1H), 6.96−7.00 (m, 1H), 7.04 (dd, J = 2.58, 8.43 Hz, 1H), 7.10 (d, J =
2.50 Hz, 1H), 7.25 (d, J = 8.45 Hz, 1H), 7.85 (t, J = 6.63 Hz, 1H), 8.15
(d, J = 5.80 Hz, 1H), 8.47 (d, J = 7.25 Hz, 1H), 8.72 (d, J = 5.20 Hz, 1H),
Table 4. Pyridyl Head Group Replacements
aIC50 values are shown as mean values of two or more determinations. Standard deviation was typically within 2-fold from the IC50. nd = not
determined. bLigand eﬃciency (LE), calculated as 0.6·ln(IC50)/(heavy atom count) using T. brucei NMT IC50 potency.
25 cEnzyme selectivity
calculated as HsNMT1 IC50 (μM)/TbNMT IC50 (μM).
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9.27 (br s, 2H). LC−MS [M +H]+ = 375.2. HRMS [M +H]+ calculated
for C23H27N4O1 = 375.2179, found = 375.2191.
1-(4-(2,6-Dimethyl-4-((2-methylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine Dihydrochloride (41). Prepared from 3-((4-
Figure 8. Hybridization approach.
Scheme 3a
aReagents and conditions: (a) 9-BBN, THF; (b) Pd(PPh3), K3PO4, H2O, DMF; (c) TFA, DCM; (d) CH2O, Na(OAc3)3BH, CHCl3.
Scheme 4a
aReagents and conditions: (a) H2SO4, EtOH; (b) phenylboronic acid, 1 M K3PO4/dioxane, Pd(PPh3)4; (c) 2 M LiAlH4 in THF, 0 °C; (d)
Pd(tBuP)2, 0.5 M isobutylzinc bromide, anhydrous THF.
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bromo-3,5-dimethylphenoxy)methyl)-2-methylpyridine (35) (150 mg,
0.49 mmol, 1 equiv) and 28 (142 mg, 0.49 mmol, 1 equiv), according to
the method outlined for the synthesis of 29, to give 41 as a
dihydrochloride salt (177 mg, 75% yield). 1H NMR 500 MHz,
DMSO δ 2.033 (s, 6H), 2.79 (s, 3H), 3.17−3.23 (m, 4H), 3.84−3.89
(m, 4H), 5.31 (s, 2H), 6.63−6.67 (m, 1H), 6.89−6.93 (m, 3H), 7.89 (t, J
= 6.70 Hz, 1H), 8.18 (d, J = 5.35 Hz, 1H), 8.51 (d, J = 7.70 Hz, 1H), 8.73
(dd, J = 1.10, 5.65 Hz, 1H), 9.36 (br s, 2H). LC−MS [M +H]+ = 389.2.
HRMS [M + H]+ calculated for C24H29N4O1 = 389.2336, found =
389.235.
tert-Butyl 4-(4-(3,5-Dichloro-4-hydroxyphenyl)pyridin-2-yl)-
piperazine-1-carboxylate (42). A solution of a tert-butyl 4-(4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-
carboxylate 28 (2.0 g, 5.14 mmol, 1.2 equiv), and 4-bromo-2,6-
dichlorophenol (25) (1.04 g, 4.3 mmol, 1 equiv) in acetonitrile (7 mL)
and aq 1MK3PO4 (5mL) was degassed by bubbling argon through for 5
min; then Pd(dppf)2Cl2 (175 mg, 0.22 mmol, 5%) was added and the
reaction degassed again for a further 5 min before microwaving at 100
°C for 30 min. The cooled solution was diluted with dichloromethane
and washed with aq NaHCO3, the dichloromethane layer was dried over
MgSO4, and the ﬁltrate was evaporated onto silica and puriﬁed by ﬂash
column chromatography running a gradient from 0% ethyl acetate/
hexane to 50% ethyl acetate/hexane to give 42 as a white solid (1.07 g,
49% yield). 1H NMR 500 MHz, CDCl3 δ 1.52 (s, 9H), 3.58−3.64 (m,
8H), 6.05 (br. s, 1H), 6.72 (s, 1H), 6.79 (d, J = 5.30, 1H), 7.53 (s, 2H),
8.25 (d, J = 5.19, 1H). [M + H]+ = 424.2.
1-(4-(3,5-Dichloro-4-(2-(pyridin-3-yl)ethoxy)phenyl)pyridin-2-yl)-
piperazine (51). Diisopropyl azodicarboxylate (DIAD, 61 μL, 0.31
mmol, 1.1 equiv) was added to a suspension of 2-(pyridin-3-yl)ethanol
(42 mg, 0.34 mmol, 1.2 equiv), polystyrene bound-PPh3 (1.84 mmol/g
loading, 200 mg, 0.37 mmol, 1.2 equiv), and 42 (120 mg, 0.28 mmol, 1
equiv) in anhydrous THF (20 mL) and then heated at 70 °C for 4 h.
After cooling, the reaction mixture was ﬁltered, the beads washed with
Table 5. Pyridyl Substitutions
aIC50 values are shown as mean values of two or more determinations. Standard deviation was typically within 2-fold from the IC50. nd = not
determined. bLigand eﬃciency (LE), calculated as 0.6·ln(IC50)/(heavy atom count) using T. brucei NMT IC50 potency.
25 cEnzyme selectivity
calculated as HsNMT1 IC50 (μM)/TbNMT IC50 (μM).
Figure 9. Comparison of 1 and 81.
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MeOH and dichloromethane, and the ﬁltrate absorbed onto silica and
puriﬁed by ﬂash column chromatography running a gradient from 0%
ethyl acetate/hexane to 100% ethyl acetate. The resulting residue was
dissolved in dichloromethane (10 mL), triﬂuoroacetic acid (10 equiv)
was added, and the reaction was stirred at RT for 16 h. The reaction was
evaporated in vacuo before loading onto a prewashed SCX cartridge. The
cartridge was washed with dichloromethane (3× 10 mL) andMeOH (3
× 10 mL) before eluting with 7 N ammonia in methanol. This was
absorbed onto silica and puriﬁed by ﬂash column chromatography
running a gradient from 0%MeOH/dichloromethane + 1%NH3 to 20%
MeOH/dichloromethane + 1% NH3 to give 51 as a white solid (35 mg,
29% yield). 1HNMR 500MHz, CDCl3 δ 3.02−3.05 (m, 4H), 3.22 (t, J =
6.90Hz, 2H), 3.58−3.61 (m, 4H), 4.30 (t, J = 6.90Hz, 2H), 6.71 (s, 1H),
6.75 (dd, J = 1.50, 5.25 Hz, 1H), 7.28−7.31 (m, 1H), 7.52 (s, 2H), 7.72−
7.74 (m, 1H), 8.25 (dd, J = 0.61, 5.24 Hz, 1H), 8.54 (dd, J = 1.61, 4.97
Hz, 1H), 8.63 (d, J = 2.11 Hz, 1H). [M +H]+ = 429.1. HRMS [M +H]+
calculated for C22H23Cl2N4O1 = 429.1243, found = 429.1245.
1-(4-(3,5-Dichloro-4-(pyridin-4-ylmethoxy)phenyl)pyridin-2-yl)-
piperazine (45). Prepared using 42 (120 mg, 0.28 mmol, 1 equiv) and
pyridin-4-ylmethanol (37 mg, 0.34 mmol, 1.2 equiv), according to the
Mitsunobu reaction and BOC deprotection procedure outlined for the
synthesis 51, to give 45 as an oﬀ-white solid (1 mg, 1% yield). 1H NMR
500 MHz, CDCl3 δ 3.04−3.06 (m, 4H), 3.61−3.63 (m, 4H), 5.14 (s,
2H), 6.74 (s, 1H), 6.78 (dd, J = 1.52, 5.39 Hz, 1H), 7.52−7.53 (m, 2H),
7.58 (s, 2H), 8.28 (d, J = 5.25 Hz, 1H), 8.69 (dd, J = 1.80, 5.94 Hz, 2H).
[M + H]+ = 415.1.
1-(4-(3,5-Dichloro-4-(pyridin-3-ylmethoxy)phenyl)pyridin-2-yl)-
piperazine (46). Prepared using 42 (120 mg, 0.28 mmol, 1 equiv) and
pyridin-3-ylmethanol (33 μL, 0.34 mmol, 1.2 equiv), according to the
Mitsunobu reaction and BOC deprotection procedure outlined for the
synthesis 51, to give 46 as an oﬀ-white solid (17 mg, 15% yield). 1H
NMR 500 MHz, CDCl3 δ 3.06−3.11 (m, 4H), 3.63−3.67 (m, 4H), 5.15
(s, 2H), 6.74 (s, 1H), 6.79 (s, 1H), 7.37−7.41 (m, 1H), 7.55−7.58 (m,
2H), 7.96−7.99 (m, 1H), 8.26−8.28 (m, 1H), 8.64−8.67 (m, 1H),
8.77−8.80 (m, 1H). [M + H]+ = 415.2. HRMS [M + H]+ calculated for
C21H21Cl2N4O1 = 415.1087, found = 415.1079.
1-(4-(3,5-Dichloro-4-(pyridin-2-ylmethoxy)phenyl)pyridin-2-yl)-
piperazine (47). Prepared using 42 (186 mg, 0.44 mmol, 1 equiv) and
pyridin-2-ylmethanol (58 mg, 0.53 mmol, 1.2 equiv), according to the
Mitsunobu reaction and BOC deprotection procedure outlined for the
synthesis 51, to give 47 as an oﬀ-white solid (130 mg, 71% yield). 1H
NMR 500 MHz, CDCl3 δ 3.04−3.06 (m, 4H), 3.60−3.63 (m, 4H), 5.25
(s, 2H), 6.74 (d, J = 5.29Hz, 1H), 6.78 (s, 1H), 7.29 (d, J = 1.26Hz, 2H),
7.30−7.32 (m, 1H), 7.80−7.86 (m, 2H), 8.27 (d, J = 5.25 Hz, 1H), 8.63
(d, J = 4.30 Hz, 1H). [M + H]+ = 415.1. HRMS [M + H]+ calculated for
C21H21Cl2N4O1 = 415.1087, found = 415.1088.
1-(4-(3,5-Dichloro-4-((2,6-dimethylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine (48). Prepared using 42 (200 mg, 0.44 mmol, 1
equiv) and (2,6-dimethylpyridin-3-yl)methanol (43) (for synthesis see
Supporting Information) (78 mg, 0.57 mmol, 1.2 equiv), according to
the Mitsunobu reaction and BOC deprotection procedure outlined for
the synthesis 51, to give 48 as an oﬀ-white solid (130 mg, 63% yield). 1H
NMR 500 MHz, CDCl3 δ 2.59 (s, 3H), 2.72 (s, 3H), 3.0−3.07 (m, 4H),
3.60−3.63 (m, 4H), 5.11 (s, 2H), 6.74 (s, 1H), 6.78 (d, J = 5.27 Hz, 1H),
7.07 (d, J = 7.81Hz, 1H), 7.57 (s, 2H), 7.76 (d, J = 7.81Hz, 1H), 8.27 (d,
J = 5.16 Hz, 1H). [M + H]+ = 443.1. HRMS [M + H]+ calculated for
C23H25Cl2N4O1 = 443.14, found = 443.1402.
1-(4-(3,5-Dichloro-4-((2,4-dimethylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine) (49). Prepared using 42 (112 mg, 0.28 mmol, 1
equiv) and (2,6-dimethylpyridin-4-yl)methanol (44) (for synthesis see
Supporting Information) (44 mg, 0.32 mmol, 1.2 equiv), according to
the Mitsunobu reaction and BOC deprotection procedure outlined for
the synthesis 51, to give 49 as an oﬀ-white solid (56 mg, 49% yield). 1H
NMR 500 MHz, DMSO δ 2.44 (s, 3H), 2.68 (s, 3H), 2.93−2.99 (m,
4H), 3.60−3.68 (m, 4H), 5.24 (s, 2H), 7.00 (d, J = 5.20 Hz, 1H), 7.10−
7.14 (m, 2H), 7.96 (s, 2H), 8.16 (d, J = 5.1 Hz, 1H), 8.29 (d, J = 5.13 Hz,
1H). [M +H]+ = 443.2. HRMS [M+H]+ calculated for C23H25Cl2N4O1
= 443.1400, found = 443.1392.
1-(4-(3,5-Dichloro-4-(2-(pyridin-2-yl)ethoxy)phenyl)pyridin-2-yl)-
piperazine (50). Prepared using 42 (120mg, 0.28 mmol, 1 equiv) and 2-
(2-hydroxyethyl)pyridine (38 μL, 0.34 mmol, 1.2 equiv), according to
the Mitsunobu reaction and BOC deprotection procedure outlined for
the synthesis 51, to give 50 as an oﬀ-white solid (24 mg, 20% yield). 1H
NMR 500 MHz, CDCl3 δ 3.02−3.05 (m, 4H), 3.39 (t, J = 6.75 Hz, 2H),
3.58−3.61 (m, 4H), 4.49 (t, J = 6.65 Hz, 2H), 6.71 (s, 1H), 6.75 (dd, J =
1.50 Hz, 5.25, 1H), 7.18−7.21 (m, 1H), 7.39 (d, J = 7.93 Hz, 1H), 7.51
(s, 2H), 7.65−7.69 (m, 1H), 8.25 (dd, J = 0.64, 5.25 Hz, 1H), 8.58−8.60
(m, 1H). [M + H]+ = 429.1. HRMS [M + H]+ calculated for
C22H23Cl2N4O1 = 429.1243, found = 429.1231.
1-(4-(3,5-Dichloro-4-(2-(pyridin-4-yl)ethoxy)phenyl)pyridin-2-yl)-
piperazine) (52). Prepared using 42 (112 mg, 0.28 mmol, 1 equiv) and
4-(2-hydroxyethyl)pyridine (42 mg, 0.34 mmol, 1.2eq) according to the
Mitsunobu reaction and BOC deprotection procedure outlined for the
synthesis 51, to give 52 as an oﬀ-white solid (22 mg, 18% yield). 1H
NMR 500 MHz, CDCl3 δ 3.02−3.05 (m, 4H), 3.22 (t, J = 6.68 Hz, 2H),
3.58−3.61 (m, 4H), 4.33 (t, J = 6.68 Hz, 2H), 6.71 (s, 1H), 6.75 (dd, J =
1.44 Hz, 5.25, 1H), 7.33 (dd, J = 1.59, 5.96 Hz, 2H), 7.53 (s, 2H), 8.25
(dd, J = 0.57, 5.19 Hz, 1H), 8.58 (dd, J = 1.54, 4.22 Hz, 2H). [M +H]+ =
429.1. HRMS [M + H]+ calculated for C22H23Cl2N4O1 = 429.123956,
found = 429.123956.
Compounds 56−67 were synthesized using the standard Mitsunobu
coupling conditions followed by BOC deprotection using TFA from 42
according to the procedure outlined in the synthesis of 51 or, in the case
of 56, using the methodology used for compound 29.
3-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-5-methylisoxazole Dihydrochloride (56). 4-Bromo-2,6-di-
chlorophenol (500 mg, 2.07 mmol, 1 equiv) and (5-methylisoxazol-3-
yl)methanol (351 mg, 3.10 mmol, 1.5 equiv) were reacted according to
the method outlined for 27 to give 3-((4-bromo-2,6-dichlorophenoxy)-
methyl)-5-methylisoxazole as a white solid (348 mg, 50% yield). 1H
NMR 500MHz, CDCl3 δ 2.46 (d, J = 0.85 Hz, 3H), 5.08 (s, 2H), 6.28−
6.29 (m, 1H), 7.48 (s, 2H). LC−MS [M + H]+ = 337.9.
3-((4-Bromo-2,6-dichlorophenoxy)methyl)-5-methylisoxazole (100
mg, 0.30 mmol, 1 equiv) and 28 (86 mg, 0.30 mmol, 1 equiv) were
reacted according to the method outlined for the synthesis of 29 to give
56 as a dihydrochloride salt (104 mg, 71% yield). 1H NMR 300 MHz,
DMSO δ 2.45 (s, 3H), 3.17−3.26 (m, 4H), 3.90−3.97 (m, 4H), 5.14 (s,
2H), 6.48−6.50 (m, 1H), 7.24 (d, J = 6.03 Hz, 1H), 7.37−7.40 (m, 1H),
8.07 (s, 2H), 8.20 (d, J = 5.73 Hz, 1H), 9.36 (br s, 2H). LC−MS [M +
H]+ = 419.1. HRMS [M + H]+ calculated for C20H21N4O2Cl2 =
419.1042, found = 419.1032.
5-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-2,4-dimethylthiazole (57). Prepared using 42 (200 mg, 0.47
mmol, 1 equiv) and (2,4-dimethyl-1,3-thiazol-5-yl)methanol (82 mg,
0.57 mmol, 1.2 equiv), according to the Mitsunobu reaction and BOC
deprotection procedure outlined for the synthesis of 51, to give 57 as an
oﬀ-white solid (70 mg, 36% yield). 1HNMR 500MHz, CDCl3 δ 2.46 (s,
3H), 2.71 (s, 3H), 3.04−3.07 (m, 4H), 3.61−3.64 (m, 4H), 5.19 (s, 2H),
6.73 (s, 1H), 6.77 (d, J = 5.27, 1H), 7.56 (s, 2H), 8.26 (d, J = 5.27 Hz,
1H). [M + H]+ = 449.0913. HRMS [M + H]+ calculated for
C21H23Cl2N4O1S1 = 449.0964, found = 449.0949.
5-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-2,4-dimethyloxazole (58). Prepared using 42 (120 mg, 0.28
mmol, 1 equiv) and (2,4-dimethyloxazol-5-yl)methanol (51) (see
Supporting Information for synthesis) (53 mg, 0.42 mmol, 1.5 equiv),
according to the Mitsunobu reaction and BOC deprotection procedure
outlined for the synthesis of 51, to give 58 as an oﬀ-white solid (20 mg,
17% yield). 1H NMR 500 MHz, CDCl3 δ 2.09 (s, 3H), 2.47 (s, 3H),
3.03−3.06 (m, 4H), 3.60−3.63 (m, 4H), 5.10 (s, 2H), 6.72 (s, 1H), 6.77
(dd, J = 1.28, 5.11 Hz, 1H), 7.54 (s, 2H), 8.26 (d, J = 5.18 Hz, 1H). [M +
H]+ = 433.2. HRMS [M + H]+ calculated for C21H23Cl2N4O2 =
433.1193, found = 433.1200.
4-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-2,5-dimethyloxazole (59). Prepared using 42 (120 mg, 0.28
mmol, 1 equiv) and (2,5-dimethyl-1,3-oxazol-4-yl)methanol (53 mg,
0.42 mmol, 1.5 equiv), according to the Mitsunobu reaction and BOC
deprotection procedure outlined in the synthesis of 51, to give 59 as an
oﬀ-white solid (27 mg, 22% yield). 1HNMR 500MHz, CDCl3 δ 2.37 (s,
3H), 2.46 (s, 3H), 3.03−3.06 (m, 4H), 3.60−3.62 (m, 4H), 4.97 (s, 2H),
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6.73 (s, 1H), 6.77 (dd, J = 1.53, 5.21 Hz, 1H), 7.55 (s, 2H), 8.26 (dd, J =
0.61, 5.21 Hz, 1H). [M + H]+ = 433.1.
4-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-2-methylthiazole (60). Prepared using 42 (150 mg, 0.35
mmol, 1 equiv) and 2-(2-methyl-1,3-thiazol-4-yl)methanol (54 mg, 0.42
mmol, 1.2 equiv), according to the Mitsunobu reaction and BOC
deprotection procedure outlined for the synthesis of 51, to give 60 as an
oﬀ-white solid (15 mg, 10% yield). 1HNMR 500MHz, CDCl3 δ 2.77 (s,
3H), 3.03−3.06 (m, 4H), 3.60−3.62 (m, 4H), 5.22 (s, 2H), 6.74 (s, 1H),
6.77 (dd, J = 1.45, 5.10 Hz, 1H), 7.37 (s, 1H), 7.56 (s, 2H), 8.26 (d, J =
5.22 Hz, 1H). [M + H]+ = 435.1.
2-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)thiazole (61). Prepared using 42 (120 mg, 0.28 mmol, 1 equiv)
and 2-(hydroxymethyl)-1,3-thiazole (48 mg, 0.42 mmol, 1.5 equiv),
according to the Mitsunobu reaction and BOC deprotection procedure
outlined in the synthesis of 51, to give 61 as an oﬀ-white solid (24 mg,
20% yield). 1HNMR 500MHz, CDCl3 δ 3.03−3.06 (m, 4H), 3.60−3.62
(m, 4H), 5.44 (s, 2H), 6.73 (s, 1H), 6.77 (dd, J = 1.41, 5.14Hz, 1H), 7.48
(d, J = 3.30 Hz, 1H), 7.57 (s, 2H), 7.86 (d, J = 3.30 Hz, 1H), 8.27 (d, J =
3.30 Hz, 1H). [M + H]+ = 423.1. HRMS [M + H]+ calculated for
C19H19Cl2N4O1S1 = 421.0651, found = 421.0641.
4-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)thiazole (62). Prepared using 42 (120 mg, 0.28 mmol, 1 equiv)
and 4-(hydroxymethyl)1,3-thiazole (48 mg, 0.42 mmol, 1.5 equiv),
according to the Mitsunobu reaction and BOC deprotection procedure
outlined for the synthesis of 51, to give 62 as an oﬀ-white solid (5mg, 4%
yield). 1H NMR 500 MHz, CDCl3 δ 3.03−3.06 (m, 4H), 3.60−3.62 (m,
4H), 5.34 (s, 2H), 6.74 (s, 1H), 6.78 (dd, J = 1.47, 5.23 Hz, 1H), 7.57 (s,
2H), 7.62−7.63 (m, 1H), 8.27 (dd, J = 0.68, 5.13 Hz, 1H), 8.87 (d, J =
2.09 Hz, 1H). [M + H]+ = 423.1.
5-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-4-methylthiazole (63). Prepared using 42 (120 mg, 0.28
mmol, 1 equiv) and (4-methylthiazol-5-yl)methanol (52) (for synthesis,
see Supporting Information) (54 mg, 0.42 mmol, 1.5 equiv), according
to the Mitsunobu reaction and BOC deprotection procedure outlined
for the synthesis of 51, to give 63 as an oﬀ-white solid (9 mg, 7% yield).
1H NMR 500 MHz, CDCl3 δ 2.56 (s, 3H), 3.03−3.06 (m, 4H), 3.60−
3.63 (m, 4H), 5.28 (s, 2H), 6.73 (s, 1H), 6.77 (dd, J = 1.46, 5.19Hz, 1H),
7.57 (s, 2H), 8.27 (dd, J = 0.6, 5.19 Hz, 1H), 8.79 (s, 1H). [M + H]+ =
435.1. HRMS [M + H]+ calculated for C20H21Cl2N4O1S1 = 435.0808,
found = 435.0809.
5-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-2-ethyl-4-methylthiazole (64). Prepared using 42 (120 mg,
0.28 mmol, 1 equiv) and (2-ethyl-4-methyl-1,3-thiazol-5-yl)methanol
(66 mg, 0.42 mmol, 1.5 equiv), according to theMitsunobu reaction and
BOC deprotection procedure outlined for the synthesis of 51, to give 64
as an oﬀ-white solid (26 mg, 20% yield). 1H NMR 500 MHz, CDCl3 δ
1.41 (t, J = 7.81, 3H), 2.47 (s, 3H), 3.00−3.06 (m, 6H), 3.60−3.62 (m,
4H), 5.19 (s, 2H), 6.73 (s, 1H), 6.77 (dd, J = 1.42, 5.20 Hz, 1H), 7.56 (s,
2H), 8.26 (d, J = 5.13 Hz, 1H). [M + H]+ = 463.1. HRMS [M + H]+
calculated for C22H25Cl2N4O1S1 = 463.1121, found = 463.1124.
5-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)thiazole (65). Prepared using 42 (120 mg, 0.28 mmol, 1 equiv)
and 5-(hydroxymethyl)-1,3-thiazole (48 mg, 0.42 mmol, 1.5 equiv),
according to the Mitsunobu reaction and BOC deprotection procedure
outlined for the synthesis of 51, to give 65 as an oﬀ-white solid (23 mg,
20% yield). 1HNMR 500MHz, CDCl3 δ 3.06−3.08 (m, 4H), 3.64−3.66
(m, 4H), 5.33 (s, 2H), 6.73 (s, 1H), 6.78 (dd, J = 1.45, 5.20Hz, 1H), 7.56
(s, 2H), 7.96 (s, 1H), 8.27 (d, J = 5.37 Hz, 1H), 8.90 (s, 1H). [M +H]+ =
421.1, 423.1. HRMS [M + H]+ calculated for C19H19Cl2N4O1S1 =
421.0651, found = 421.064.
5-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-2-isopropyl-4-methylthiazole (66). Prepared using 42 (120
mg, 0.28 mmol, 1 equiv) and (2-isopropyl-4-methylthiazol-5-yl)-
methanol (53) (for synthesis, see Supporting Information) (73 mg,
0.42 mmol, 1.5 equiv), according to the Mitsunobu reaction and BOC
deprotection procedure outlined for the synthesis of 51, to give 66 as an
oﬀ-white solid (37 mg, 28% yield). 1HNMR 500MHz, CDCl3 δ 1.42 (d,
J = 7.12 Hz, 6H), 2.48 (s, 2H), 3.03−3.06 (m, 4H), 3.31 (sept, J = 6.97
Hz, 1H), 3.60−3.63 (m, 4H), 5.19 (s, 2H), 6.73 (s, 1H), 6.77 (dd, J =
1.36, 5.23 Hz, 1H), 7.57 (s, 2H), 8.27 (dd, J = 0.68, 5.23 Hz, 1H). [M +
H]+ = 477.2. HRMS [M + H]+ calculated for C23H27Cl2N4O1S1 =
477.1277, found = 477.1273.
4-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)-2-isopropylthiazole (67). Prepared using 42 (120 mg, 0.28
mmol, 1 equiv) and 4-(hydroxymethyl)-2-isopropylthiazole (66 mg,
0.42 mmol, 1.5 equiv), according to the Mitsunobu reaction and BOC
deprotection procedure outlined for the synthesis of 51, to give 67 as an
oﬀ-white solid (1 mg, 1% yield). 1H NMR 500 MHz, CDCl3 δ 1.43 (d, J
= 6.85 Hz, 6H), 3.03−3.05 (m, 4H), 3.36 (sept, J = 6.95 Hz, 1H), 3.60−
3.62 (m, 4H), 5.26 (s, 2H), 6.74 (s, 1H), 6.78 (dd, J = 1.47, 5.18Hz, 1H),
7.55 (s, 2H), 8.26 (d, J = 5.12 Hz, 1H). [M + H]+ = 463.1.
3-((2,6-Dichloro-4-(3-(piperidin-4-yl)propyl)phenoxy)methyl)-2-
methylpyridine (70). To a solution of tert-butyl 4-(but-3-en-1-
yl)piperidine-1-carboxylate (0.58 g, 2.4 mmol, 2 equiv) under argon
in anhydrous THF (1 mL) was added 9-BBN (5.1 mL (0.5 M in THF),
2.55 mmol, 2.1 equiv), and the reaction was heated to 90 °C for 1 h in a
microwave. To this crude reaction, 3-((4-bromo-2,6-dichlorophenoxy)-
methyl)-2-methylpyridine (0.42 g, 1.2 mmol, 1 equiv) and K3PO4 (1 M
in H2O, 2.4 mmol, 2.4 mL, 2 equiv) in anhydrous DMF (2.5 mL) was
added and then degassed with argon. (Pd(PPh3)4 (0.024 mmol, 28 mg,
2%) was then added, and the solution was microwaved at 110 °C for 1 h.
The reaction was extracted into dichloromethane, washed with water,
and dried over MgSO4. The crude material was puriﬁed by ﬂash column
chromatography, running a gradient from 0% ethyl acetate in hexane to
50% ethyl acetate in hexane. The Boc protected 70 was taken up in
dichloromethane (12 mL), triﬂuoroacetic acid added (6 mL), and the
reaction stirred for 2 h. The solvent was removed in vacuo to give a crude
residue, which was puriﬁed by SCX-2, eluting with methanol to 2 M
methanolic ammonia, followed by column chromatography, eluting with
dichloromethane to dichloromethane−methanol (80:20) with 1%NH3,
to give 70 (0.105g, 10%) as an oil. 1H NMR 500 MHz, CDCl3 δ 1.05−
1.13 (m, 2H), 1.23−1.40 (m, 5H), 1.58−1.62 (m, 7H), 2.57 (dd, J = 7.7,
7.7 Hz, 2H), 2.70 (s, 3H), 4.07−4.10 (m, 2H), 5.05 (s, 2H), 7.16 (s, 2H),
7.21 (dd, J = 4.9, 7.6 Hz, 1H), 7.90 (dd, J = 1.5, 7.6 Hz, 1H), 8.52 (dd, J =
1.7, 4.9 Hz, 1H). HRMS [M + H]+ calculated for C22H23Cl2N4O =
429.124343, found = 429.124407.
3-((2,6-Dichloro-4-(3-(1-methylpiperidin-4-yl)propyl)phenoxy)-
methyl)-2-methylpyridine (71). 3-((2,6-Dichloro-4-(3-(piperidin-4-
yl)propyl)phenoxy)methyl)-2-methylpyridine (70) (0.07 g, 0.17
mmol, 1 equiv) was taken up in chloroform (10 mL), treated with
paraformaldehyde (0.052 g, 10 equiv), and heated at 55 °C for 1 h. The
reaction mixture was then treated with sodium triacetoxyborohydride
(0.183 g, 0.86 mmol, 5 equiv), and heating continued for 16 h. The
reaction mixture was cooled to room temperature and then partitioned
between dichloromethane and sodium bicarbonate solution. The
dichloromethane layer was separated and dried over MgSO4 and
solvent removed. The crude material was puriﬁed by column
chromatography, eluting with dichloromethane to dichloromethane−
methanol (95:5) with 1% NH3 to give (71) as a white solid (58 mg, 76%
yield). 1H NMR 500 MHz, CDCl3 δ 1.23−1.30 (m, 5H), 1.34−1.39 (m,
2H), 1.87−1.92 (m, 2H), 2.27 (s, 3H), 2.56 (dd, J = 7.8, 7.8 Hz, 2H),
2.70 (s, 4H), 2.85 (d, J = 11.3Hz, 2H), 5.05 (s, 2H), 5.33 (s, 1H), 7.16 (s,
2H), 7.21 (dd, J = 5.1, 7.6 Hz, 1H), 7.90 (dd, J = 1.6, 7.6 Hz, 1H), 8.52
(dd, J = 1.7, 4.8 Hz, 1H). [M + H]+ = 421.1889. HRMS [M + H]+
calculated for C23H31Cl2N2O1 = 421.1808, found = 421.1802.
Ethyl 2-Chloronicotinate (72) and Ethyl 2-Ethoxynicotinate (75).
To a suspension of 2-chloronicotinic acid (4.6 g, 29.2 mmol) in ethanol
(50 mL), conc. H2SO4 (2 mL) was added dropwise, and the suspension
was heated to reﬂux for 3 h to form a solution. The reaction was then
cooled and evaporated in vacuo, then carefully neutralized with sat. aq
NaHCO3 and extracted into ethyl acetate. The organic layer was washed
with water and then dried overMgSO4, ﬁltered, absorbed onto silica, and
puriﬁed using ﬂash column chromatography running a gradient from 0%
ethyl acetate/hexane to 50% ethyl acetate/hexane, to give the title
compounds (ethyl 2-chloronicotinate 72, bottom spot, 2.33 g, 43%
yield; ethyl 2-ethoxynicotinate 75, top spot, 923mg, 16% yield). Ethyl 2-
chloronicotinate (72) 1H NMR 500 MHz, CDCl3 δ 1.45 (t, J = 7.61 Hz,
3H), 4.45 (q, J = 7.07Hz, 2H), 7.36 (dd, J = 4.76, 7.71 Hz, 1H), 8.19 (dd,
J = 2.09, 7.87 Hz, 1H), 8.54 (dd, J = 2.09, 4.77 Hz, 1H). [M + H]+ =
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186.1. Ethyl 2-ethoxynicotinate (75) 1H NMR 500 MHz, CDCl3 δ 1.14
(t, J = 7.06 Hz, 3H), 1.47 (t, J = 6.92 Hz, 3H), 4.39 (q, J = 7.20 Hz, 2H),
4.50 (q, J = 7.06 Hz, 2H), 6.94 (dd, J = 4.98, 7.48 Hz, 1H), 8.16 (dd, J =
2.01, 7.48 Hz, 1H), 8.30 (dd, J = 2.01, 4.88 Hz, 1H). [M + H]+ = 196.1.
Prototypical Negishi Reaction between a Chloropyridine and
Alkylzinc Bromide. Ethyl 2-Isobutylnicotinate (74a). Anhydrous THF
(9 mL) was added to a ﬂame-dried argon purged ﬂask containing ethyl
2-chloronicotinate (72) (227mg, 1.2 mmol, 1 equiv) and Pd(tBuP)2 (31
mg, 0.06 mmol, 5%), and the mixture was stirred until clear. To this,
isobutylzinc bromide (0.5 M in THF, 2.6 mL, 1.3 mmol, 1.1 equiv) was
added dropwise, and the resulting solution was heated at 60 °C
overnight. The reaction was absorbed onto silica and eluted to remove
baseline material before purifying again by ﬂash column chromatog-
raphy using 25% ethyl acetate/hexane as the eluent, to give 74a as a
yellow oil (164mg, 66% yield). 1HNMR 500MHz, CDCl3 δ 0.95 (d, J =
6.75Hz, 6H), 1.43 (t, J = 7.25Hz, 3H), 2.13 (sept, J = 6.75Hz, 1H), 3.11
(d, J = 7.25 Hz, 2H), 4.41 (q, J = 7.13 Hz, 2H), 8.16 (dd, J = 1.88, 7.75
Hz, 1H), 8.67 (dd, J = 1.88, 4.75 Hz, 1H). [M + H]+ = 208.
Prototypical Suzuki Reaction of a Chloropyridine and Boronic
Acid. Ethyl 2-Phenylnicotinate (73). A solution of ethyl 2-
chloronicotinate (72) (793 mg, 4.3 mmol, 1 equiv) and phenylboronic
acid (773mg, 6.4 mmol, 1.5 equiv) in 1M aqK3PO4 (4mL) and dioxane
(6 mL) in a microwave vessel was degassed with argon for 5 min before
addition of Pd(PPh3)4 (64 mg, 0.055 mmol, 5%) and degassing again for
a further 5 min before microwaving at 140 °C for 15 min. The reaction
mixture was partitioned between dichloromethane and sat. aq NaHCO3,
and the organic layer was absorbed onto silica and puriﬁed by ﬂash
column chromatography running a gradient from 0% ethyl acetate/
hexane to 25% ethyl acetate/hexane, aﬀording 73 as an oil (927 mg, 95%
yield). 1H NMR 500 MHz, CDCl3 δ 1.07 (t, J = 7.19 Hz, 3H), 4.18 (q, J
= 7.19 Hz, 2H), 7.37 (dd, J = 4.91, 7.87 Hz, 1H), 7.45−7.48 (m, 3H),
7.55−7.57 (m, 2H), 8.14 (dd, J = 1.71, 7.76 Hz, 1H), 8.79 (dd, J = 1.83,
4.78 Hz, 1H). [M + H]+ = 228.2.
Prototypical Pyridyl Ester Reduction to an Alcohol. (2-iso-
Butylpyridin-3-yl)methanol (77a). To a solution of ethyl 2-iso-
butylnicotinate 74a (774 mg, 3.7 mmol, 1 equiv) in anhydrous THF
(5 mL) at 0 °C, 0.5 M LiAlH4 in THF (5.6 mL, 11.2 mmol, 3 equiv) was
added dropwise, and the solution was allowed to warm to room
temperature before being stirred at rt for 16 h. Sodium sulﬁte
decahydrate was added to the solution, and the reaction was diluted
with dichloromethane and allowed to stir for 30 min. The reaction was
ﬁltered, the ﬁltrate layers separated, and the organic layer dried over
MgSO4 and evaporated in vacuo to give 77a as a yellow oil (452 mg, 74%
yield). 1HNMR 500MHz, CDCl3 δ 0.97 (d, J = 6.67, 6H), 2.19 (sept, J =
6.82 Hz, 1H), 2.71 (d, J = 7.42 Hz, 2H), 4.79 (d, J = 5.51 Hz, 2H), 7.17
(dd, J = 4.78, 7.82 Hz, 1H), 7.60 (d, J = 7.68 Hz, 1H), 8.50 (dd, J = 1.74,
4.78 Hz, 1H). [M + H] = 166.2.
1-(4-(3,5-Dichloro-4-((2-ethoxypyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine (79). Prepared using 42 (200 mg, 0.47 mmol, 1
equiv) and (2-ethoxypyridin-3-yl)methanol (78) (87 mg, 0.57 mmol,
1.2 equiv), according to the Mitsunobu reaction and BOC deprotection
procedure outlined for the synthesis of 51, to give 79 as an oﬀ-white
solid (30 mg, 33% yield). 1H NMR 500 MHz, CDCl3 δ 1.42 (t, J = 7.21
Hz, 3H), 2.66−2.69 (m, 4H), 3.65−3.68 (m, 4H), 4.41 (q, J = 7.07 Hz,
2H), 6.72 (dd, J = 1.42, 5.21 Hz, 1H), 6.90 (dd, J = 5.04, 7.20 Hz, 1H),
7.53 (s, 1H), 7.72 (dd, J = 1.61, 7.50 Hz, 1H), 8.09 (dd, J = 1.96, 5.04 Hz,
1H), 8.24 (d, J = 5.24 Hz, 1H). [M + H]+ = 459.2. HRMS [M + H]+
calculated for C23H25Cl2N4O2 = 459.1349, found = 459.1339.
4-(3-((2,6-Dichloro-4-(2-(piperazin-1-yl)pyridin-4-yl)phenoxy)-
methyl)pyridin-2-yl)morpholine (80). Prepared using 42 (200 mg, 0.47
mmol, 1 equiv) and (2-morpholinopyridin-3-yl)methanol (110mg, 0.57
mmol, 1.2 equiv), according to the Mitsunobu reaction and BOC
deprotection procedure outlined for the synthesis of 51, to give 80 as an
oﬀ-white solid (58 mg, 28% yield). 1H NMR 500 MHz, CDCl3 δ 3.04−
3.06 (m, 4H), 3.28−3.31 (m, 4H), 3.60−3.63 (m, 4H), 3.88−3.90 (m,
4H), 5.15 (s, 2H), 6.74 (s, 1H), 6.79 (dd, J = 1.48, 5.29 Hz, 1H), 7.60 (s,
2H), 8.07 (dd, J = 1.93, 7.51 Hz, 1H), 8.28 (d, J = 5.23Hz, 1H), 8.37 (dd,
J = 1.93, 4.89 Hz, 1H). [M + H]+ = 500.2. HRMS [M + H]+ calculated
for C25H28Cl2N5O2 = 500.161457, found = 500.160771.
1-(4-(3,5-Dichloro-4-((2-isobutylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine (81). Prepared using 42 (200 mg, 0.47 mmol, 1
equiv) and (2-isobutylpyridin-3-yl)methanol (77a) (94 mg, 0.57 mmol,
1.2 equiv), according to the Mitsunobu reaction and BOC deprotection
procedure outlined for the synthesis 51, to give 81 as an oﬀ-white solid
(86 mg, 40% yield). 1H NMR 500 MHz, CDCl3 δ 1.00 (d, J = 6.69 Hz,
6H), 2.23 (sept, J = 6.91 Hz, 1H), 3.04−3.06 (m, 4H), 3.60−3.63 (m,
4H), 5.14 (s, 2H), 6.74 (s, 1H), 6.78 (dd, J = 1.44, 5.11 Hz, 1H), 7.23
(dd, J = 4.75, 7.63 Hz, 1H), 7.59 (s, 2H), 7.98 (dd, J = 1.73, 7.77Hz, 1H),
8.28 (dd, J = 0.65, 5.18 Hz, 1H), 8.60 (dd, J = 1.82, 4.86 Hz, 1H). [M +
H]+ = 471.2. HRMS [M + H]+ calculated for C25H29Cl2N4O1 =
471.1713, found = 471.1718.
1-(4-(3,5-Dichloro-4-((2-phenylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine (82). Prepared using 42 (200 mg, 0.47 mmol, 1
equiv) and (2-phenylpyridin-3-yl)methanol 76 (for synthesis, see
Supporting Information) (105 mg, 0.57 mmol, 1.2 equiv), according
to the Mitsunobu reaction and BOC deprotection procedure outlined in
the synthesis of 51, to give 82 as an oﬀ-white solid (122 mg, 53% yield).
1H NMR 500 MHz, CDCl3 δ 3.03−3.05 (m, 4H), 3.60−3.62 (m, 4H),
5.14 (s, 2H), 6.71 (s, 1H), 6.76 (dd, J = 1.44, 5.24 Hz, 1H), 7.41 (dd, J =
4.76, 7.68 Hz, 1H), 7.45−7.51 (m, 3H), 7.53 (s, 2H), 7.65−7.67 (m,
2H), 8.22 (dd, J = 1.65, 7.82Hz, 1H), 8.26 (d, J = 5.21Hz, 1H), 8.74 (dd,
J = 1.71, 4.78 Hz, 1H). [M + H]+ = 491.2. HRMS [M + H]+ calculated
for C27H25Cl2N4O1 = 491.14, found = 491.1405.
1-(4-(3,5-Dichloro-4-((2-propylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine (83). Prepared using 42 (150 mg, 0.35 mmol, 1
equiv) and (2-propylpyridin-3-yl)methanol (77b) (for synthesis, see
Supporting Information) (63 mg, 0.42 mmol, 1.2 equiv), according to
the Mitsunobu reaction and BOC deprotection procedure outlined for
the synthesis of 51, to give 83 as an oﬀ-white solid (33 mg, 21% yield).
1H NMR 500 MHz, CDCl3 δ 1.06 (t, J = 7.53 Hz, 3H), 1.79−1.87 (m,
2H), 2.96−2.99 (m, 2H), 3.04−3.06 (m, 4H), 3.60−3.63 (m, 4H), 5.14
(s, 2H), 6.74 (s, 1H), 6.78 (dd, J = 1.40, 5.20 Hz, 1H), 7.23 (dd, J = 4.86,
7.55 Hz, 1H), 7.59 (s, 2H), 7.95 (dd, J = 1.73, 7.66 Hz, 1H), 8.28 (dd, J =
0.70, 5.14 Hz, 1H), 8.59 (dd, J = 1.73, 4.87 Hz, 1H). [M + H]+ = 457.2.
HRMS [M + H]+ calculated for C24H27Cl2N4O1 = 457.1556, found =
457.1552.
1-(4-(3,5-Dichloro-4-((2-isopentylpyridin-3-yl)methoxy)phenyl)-
pyridin-2-yl)piperazine (84). Prepared using 42 (150 mg, 0.35 mmol, 1
equiv) and (2-isopentylpyridin-3-yl)methanol (77c) (for synthesis, see
Supporting Information) (75 mg, 0.42 mmol, 1.2 equiv), according to
the Mitsunobu reaction and BOC deprotection procedure outlined for
the synthesis of 51, to give 84 as an oﬀ-white solid (109 mg, 65% yield).
1H NMR 500 MHz, CDCl3 δ 1.00 (d, J = 6.84 Hz, 6H), 1.65−1.72 (m,
2H), 1.73 (sept, J = 6.87 Hz, 1H), 2.97−3.01 (m, 2H), 3.03−3.06 (m,
4H), 3.60−3.63 (m, 4H), 5.14 (s, 2H), 6.74 (s, 1H), 6.78 (dd, J = 1.39,
5.16 Hz, 1H), 7.22 (dd, J = 4.79, 7.74 Hz, 1H), 7.58 (s, 2H), 7.95 (dd, J =
1.80, 7.70 Hz, 1H), 8.28 (dd, J = 0.61, 5.12 Hz, 1H), 8.58 (dd, J = 1.76,
4.92 Hz, 1H). [M + H]+ = 485.2. HRMS [M + H]+ calculated for
C26H31Cl2N4O1 = 485.1869, found = 485.1888.
X-ray Crystallography Methods. AfNMT protein−ligand com-
plexes were determined using methods described previously.30 Ternary
complexes of AfNMT with myristoyl CoA (MCoA) and ligands of
interest were obtained by cocrystallization by incubating protein with 10
mMMCoA plus 10 mM ligand diluted from a 100 mM stock in DMSO
prior to crystallization. Diﬀraction data were measured at the European
Synchrotron Radiation Facility (ESRF). Data integration and scaling
was carried out using XDS36 and AIMLESS37 or the HKL suite.38
Structures were phased by molecular replacement with MOLREP39
from the CCP4 suite40 using the protein coordinates of AfNMT−
compound 1 (PDB 4CAX) as a search model. Reﬁnement was carried
out using REFMAC5,41 and manual model alteration was carried out
using Coot.42 Ligand−coordinate and restraint ﬁles were generated
using PRODRG,43 and ligands were modeled into unbiased Fobs − Fcalc
density maps using Coot.
Coordinates for AfNMT−ligand complexes and associated diﬀrac-
tion data have been deposited in the RCSB Protein Data Bank (PDB)
with accession codes 5T5U, 5T6C, 5T6E, and 5T6H for compounds 24,
29, 48, and 49, respectively. Data measurement and reﬁnement statistics
are shown in the Supporting Information.
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NMT Enzyme Assay. NMT assays44,45 were carried out at room
temperature (22−23 °C) in 384-well white optiplates (PerkinElmer).
Each assay was performed in a 40 μL reaction volume containing 30mM
Tris buﬀer, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 1.25 mM
dithiothreitol (DTT), 0.1% (v/v) Triton X-100, 0.125 μM [3H]-
myristoyl-coA (8 Curie (Ci) mmol−1), 0.5 μM biotinylated CAP5.5, 5
nM NMT, and various concentrations of the test compound. The IC50
values for HsNMT1 and HsNMT2 were essentially identical against 80
compounds tested, and for logistical reasons, onlyHsNMT1 was used in
later studies.
Test compound (0.4 μL in DMSO) was transferred to all assay plates
using a Cartesian Hummingbird (Genomics Solution) before 20 μL of
enzyme was added to assay plates. The reaction was initiated with 20 μL
of a substrate mix and stopped after 15 min (HsNMT1 orHsNMT2) or
50 min (TbNMT) with 40 μL of a stop solution containing 0.2 M
phosphoric acid, pH 4.0, 1.5 MMgCl2, and 1 mg mL
−1 PVT SPA beads
(GE Healthcare). All reaction mix additions were carried out using a
Thermo Scientiﬁc WellMate (Matrix). Plates were sealed and read on a
TopCount NXT Microplate Scintillation and Luminescence Counter
(PerkinElmer).
ActivityBase from IDBS was used for data processing and analysis. All
IC50 curve ﬁtting was undertaken using XLFit version 4.2 from IDBS. A
four-parameter logistic dose−response curve was used using XLFit 4.2
Model 205. All test compound curves had ﬂoating top and bottom, and
preﬁt was used for all four parameters.
Compound Eﬃcacy and Trypanocidal Activity in Cultured T.
brucei Parasites.BloodstreamT. b. brucei s427 was cultured at 37 °C in
modiﬁed HMI9 medium (56 μM 1-thioglycerol was substituted for 200
μM2-mercaptoethanol) and quantiﬁed using a hemocytometer. For the
live/dead assay, cells were analyzed using a two-color cell viability assay
(Invitrogen) as described previously.22 Cell culture plates were stamped
with 1 μL of an appropriate concentration of test compound in DMSO
followed by the addition of 200 μL of trypanosome culture (104 cells
mL−1) to each well, except for one column, which received media only.
MRC-5 cells were cultured in DMEM, seeded at 2000 cells per well, and
allowed to adhere overnight. One microliter of test compound (10 point
dilutions from 50 μM to 2 nM) was added to each well at the start of the
assay. Culture plates of T. brucei and MRC-5 cells were incubated at 37
°C in an atmosphere of 5% CO2 for 69 h, before the addition of 20 μL of
resazurin (ﬁnal concentration, 50 μM). After a further 4 h incubation,
ﬂuorescence was measured (excitation 528 nm; emission 590 nm) using
a BioTek ﬂx800 plate reader.
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